Credit: eBayOlive Garden Never Ending Pasta Passes for sale on eBay. | In the wake of Olive Garden's highly successful promotion for never-ending pasta, the Italian chain faces what might be called a high-quality problem. More than 50 of the 1,000 pasta passes are drawing bids on online auction site eBay (EBAY) for multiples of the original $100 purchase price even though the restaurant stipulates on its site that they are "non-transferable and may not be re-sold." In light of this, the company faces a dilemma: it can either enforce the fine print and risk making some second-hand buyers or sellers mad, or bend the rules and not risk alienating customers. So far, the company has chosen the first path. "We're working with eBay to notify both buyers and sellers that the Never Ending Pasta Passes are non-transferable and may not be resold," said Tara Gray, a Darden (DRI) spokeswoman, by email. On Monday, the pass promotion drew half a million visitors within the first half hour. At times, the volume was so great, the promotion's site suffered technical glitches. At least one seller has been transparent about the potential issue that buyers face. User rpskoolinu, who listed two passes for $500, wrote "If the cards are marked with our name and not able to be used, I will issue a full refund. I don't know if they simply have to state the non-transferable for legal reasons or if they will implement." Many of the other listings for the pass fail to mention that they can't be re-sold. One eBay reseller that CNBC emailed planned to get around the reselling ban by leaving one of the fields for a name for the pass blank. "Yeah I don't know exactly. There isn't a name on the card. There is just my billing info. I can always tell them I bought it for the person who got it on ebay. How are they going to tell me I didn't?" he wrote in a message. For those who failed to snag a pasta pass Monday, Gray mentioned the company will be hosting giveaways during the next couple weeks leading up to the beginning of the promotion.
10 Best Promising Stocks To Own Right Now: Osiris Therapeutics Inc.(OSIR)
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. It operates in two business segments, Therapeutics and Biosurgery. The Therapeutics segment focuses on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. This segment focuses on developing biologic products for use in surgical procedures. The company?s lead biologic drug candidate is Prochymal, which is in phase 2 and 3 clinical trails for various indications, including acute graft versus host disease (GvHD), Crohn's disease, acute myocardial infarction, type 1 diabetes, pulmonary disease, and gastrointestinal injury resulting from radiation exposure. Its biologic drug candidates also include Chondrogen, a preparation of adult mesenchymal stem cells that is in phase 2 clinical trials for osteoarthritis and cartilage protection. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen in various countries except in the United States and Canada. It also has a partnership with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
Advisors' Opinion:- [By Maxx Chatsko]
Additionally, stem cell therapies have remained elusive as the industry's ultimate Holy Grail. Osiris (NASDAQ: OSIR ) received Canadian approval for the world's first stem cell drug, Prochymal, for children battling acute graft-versus-host disease, or GvHD, last year. The approval meant more symbolically than to the bottom line, but it definitely put the potential of stem cells front and center for investors.
- [By Lauren Pollock]
Osiris Therapeutics Inc.(OSIR) said Friday a proposed ruling from the Centers for Medicare and Medicaid Services won’t immediately affect reimbursements for its Grafix stem-cell product. The regenerative medicine company said Grafix will maintain its current reimbursement status — also called transitional pass-through status — potentially through late 2015.
- [By Alexander Maxwell]
One of the companies attempting to develop a better treatment for chronic diabetic foot ulcers is Osiris Therapeutics� (NASDAQ: OSIR ) . Earlier this month, Osiris shares more than doubled as the company announced positive data for its CDFU drug Grafix. The study results were very impressive to say the least; the study was stopped early due to the overwhelming efficacy exhibited by the treatment. A main highlight is the fact that 62% of Grafix patients had their wound closed at 12 weeks, compared to only 21% of patients using conventional methods. Clearly, the efficacy in this endpoint was overwhelming. Grafix also achieved all of the secondary endpoints for the trial, and more importantly demonstrated a relatively benign safety record.�
Top 10 Quality Companies To Invest In 2015: Isramco Inc.(ISRL)
Isramco, Inc., together with its subsidiaries, engages in the acquisition, development, production, and exploration of onshore oil and natural gas properties in the United States. It owns various working interests in oil and gas wells in Louisiana, Texas, New Mexico, Oklahoma, Wyoming, Utah, and Colorado; and operates approximately 589 wells principally in Texas and New Mexico. The company sells its oil and natural gas products to independent marketers, oil and natural gas companies, and gas pipeline companies. As of December 31, 2010, its estimated total proved reserves were approximately 9,031 thousand barrels of oil equivalent, which included 3,318 thousand barrels of oil, and 23,701 million cubic feet of natural gas, and 1,763 thousand barrels of natural gas liquids. The company was founded in 1982 and is based in Houston, Texas.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Isramco (Nasdaq: ISRL ) , whose recent revenue and earnings are plotted below.
Top 10 Quality Companies To Invest In 2015: World Energy Solutions Inc(DE)
World Energy Solutions, Inc. provides a range of energy management solutions to commercial and industrial businesses, institutions, utilities, and governments. It offers technology-enabled solutions, such as online audits of facilities to identify retrofit options and project management services for retrofit implementation, as well as cross-selling opportunities for commodity auctions. The company primarily focuses on retail and wholesale energy procurement clients via its online auction platforms, including the World Energy Exchange, the World Green Exchange, and the World DR Exchange. The World Energy Exchange enables energy consumers in North America to negotiate for the purchase or sale of electricity, natural gas, and other energy resources from energy suppliers who have agreed to participate on auction platform. The World Green Exchange enables buyers and sellers to negotiate for the purchase or sale of environmental commodities, such as renewable energy certificates , verified emissions reductions, and certified emissions reductions. The World DR Exchange enables curtailment service providers and energy consumers to negotiate in structured auction events designed to yield price transparency. The company was formerly known as World Energy Exchange, Inc. World Energy Solutions, Inc. was founded in 1996 and is headquartered in Worcester, Massachusetts.
Advisors' Opinion:- [By Sue Chang]
Deere (DE) �is forecast to post second-quarter earnings of $2.47 a share.
Top 10 Quality Companies To Invest In 2015: Targacept Inc.(TRGT)
Targacept, Inc., a biopharmaceutical company, engages in the discovery, design, and development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system. Its products include TC-5214, a nicotinic channel modulator, which is in Phase III clinical trials as an adjunct treatment for depressive disorder; and in Phase IIb clinical trial for switch monotherapy in patients with depressive disorder. The company?s small molecule products include TC-5619, which is under two separate Phase II clinical trials to treat negative symptoms and cognitive dysfunction in schizophrenia, inattentive-predominant attention deficit/hyperactivity disorder, and Alzheimer?s disease; AZD3480, a product under Phase IIb clinical trials for the treatment of mild to moderate Alzheimer?s disease; AZD1446 for treatment of Alzheimer?s disease; TC-6987 under Phase II clinical trials to treat asthma and type 2 diabetes; and TC-6499 for the treatm ent for gastrointestinal disorders. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation and Glaxo Group Limited to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina.
Advisors' Opinion:- [By Anna Prior]
Targacept Inc.(TRGT) �said it will drop a clinical-stage treatment for Alzheimer’s disease after seeing disappointing results in a midstage study. Shares fell 4.8% to $4.20 premarket.
- [By DailyFinance Staff]
Investors took a wait-and-see attitude Tuesday, but airline stocks lost altitude. The market is in a holding pattern until 2 p.m. Wednesday, when the Fed reveals details of this week's FOMC policy meetings, and whether it's ready to begin cutting back on its main economic stimulus program. If it does begin to taper, the next debate will begin immediately: Is that good or bad for investors? On Wall Street today, the Dow Jones industrial average (^DJI) edged down 9 points, the Nasdaq composite (^IXIC) fell nearly 6, and the Standard & Poor's 500 index (^GPSC) lost 5 points. The Dow's gainers were led by a pair of companies hiking their dividends. 3M (MMM), which makes everything from Post-It notes to medical equipment, rose 3 percent after increasing its payout by 35 percent. And Boeing (BA) rose 1 percent. It boosted the dividend by 50 percent and announced a big stock buyback. The other big blue chip winner was Visa (V), which gained another 2.5 percent. Its stock is now up 43 percent from a year ago. On the downside, Verizon (VZ), IBM (IBM), McDonald's (MCD) and Microsoft (MSFT) all lost about one percent. Microsoft says it will not name a new CEO until next year. And airline stocks were broadly lower. United (UAL) and Delta (DAL) both fell 3 percent. American Airlines (AAL), which completed its merger with U.S. Airways last week, fell 2 percent. And Southwest (V) also lost 2 percent. Brokerage recommendations gave a boost to several issues. Data storage companies Seagate (STX), up 3 percent, and Western Digital (WDC), up 2.5 percent, following JP Morgan upgrades. And iRobot (IRBT) surged 17 percent after Raymond James gave it a 'strong buy.' Shares of Facebook (FB) rose 2 percent, hitting an all-time high. The social media giant is rolling out new video ads this week. That's expected to boost revenue. The question is, will it alienate users? On the downside, Targacept (TRGT) lost more than a third of its value. A clinical trial of its schizophreni
Top 10 Quality Companies To Invest In 2015: Williams Partners L.P.(WPZ)
Williams Partners L.P. focuses on natural gas transportation, gathering, treating and processing, storage, natural gas liquid fractionation, and oil transportation activities in the United States. The company operates in two segments, Gas Pipeline, and Midstream Gas and Liquids. The Gas Pipeline segment owns and operates approximately 13,900 miles of pipelines with annual throughput of approximately 2,700 trillion British thermal units of natural gas and delivery capacity of approximately 13 million dekatherms of gas. This segment also owns interests in joint venture interstate and intrastate natural gas pipeline systems. The Midstream Gas and Liquids segment includes natural gas gathering, processing, and treating facilities; and crude oil gathering and transportation facilities that serve the producing basins in Colorado, New Mexico, Wyoming, the Gulf of Mexico, and Pennsylvania. Williams Partners GP LLC serves as the general partner of the company. Williams Partners L.P . was founded in 2005 and is based in Tulsa, Oklahoma.
Advisors' Opinion:- [By Adam Galas]
In the past I've written about why I'm a fan of Williams Companies (NYSE: WMB ) and its MLP Williams Partners (NYSE: WPZ ) , as excellent high-yield long-term investments into America's shale gas boom.�
- [By Robert Rapier]
That�� the neat trick�Williams�(NYSE: WMB) pulled off today in converting its equity investment in�Access Midstream Partners�(NYSE: ACMP) into full control that will allow it to use ACMP�� surplus �cash flow to offset the deficit at its fully sponsored�Williams Partners�(NYSE: WPZ) MLP, which is to be folded into Access. Williams shareholders get stepped up dividend growth and strategic control of valuable assets.
Top 10 Quality Companies To Invest In 2015: Mesabi Trust (MSB)
Mesabi Trust operates as a royalty trust in the United States. The company produces iron ore pellets. It holds interest in the Peter Mitchell mine located in the Mesabi Iron Range near Babbitt, Minnesota. The company holds various agreements with the Northshore Mining Company that mines iron ore, which is in the form of taconite, crushes it, separates the iron particles from the non-metallic, and forms the resulting concentrate into pellets that are shipped for use in steel-producing blast furnaces of customers of CCI, a mining company that produces iron pellets in North America. Mesabi Trust was founded in 1919 and is based in New York, New York.
Advisors' Opinion:- [By Selena Maranjian]
Patience, Grasshopper
For starters, imagine that you invested in Mesabi Trust (NYSE: MSB ) about a year ago and you're down some 20% on your investment. Your holding might be looking to you like an answer to the question, "What is investment panic, Alex?" But don't be so hasty. Ask yourself why you bought it. Mesabi Trust is a royalty trust that receives and then pays out to shareholders a portion of the proceeds from iron mined by a�Cliffs Natural Resources�subsidiary. Some might avoid it because royalty trusts often have expiration dates, but it's worth noting that Mesabi's is rather�far away. But slowdown in demand�for ore is a concern, one that has been�an issue for Cliffs, too.
Top 10 Quality Companies To Invest In 2015: Summer Infant Inc.(SUMR)
Summer Infant, Inc., through its subsidiaries, engages in the design, marketing, and distribution of branded juvenile health, safety, and wellness products primarily in North America and the United Kingdom. It offers products in various product categories, including nursery audio/video monitors, safety gates, durable bath products, bed rails, nursery products, booster and potty seats, bouncers, travel accessories, high chairs, swings, feeding products, car seats, and nursery furniture, as well as infant thermometers, related health and safety products, cribs, baby gear, swaddling blankets, and bottles. The company sells its products principally under the Summer Infant, Carter?s, and Disney brand names through mass merchant retailers and specialty retailers, as well as directly to consumers. Summer Infant, Inc. is headquartered in Woonsocket, Rhode Island.
Advisors' Opinion:- [By Lisa Levin]
Summer Infant (NASDAQ: SUMR) shares dropped 3.69% to $3.65 after the company reported Q2 results.
Nordstrom (NYSE: JWN) tumbled 3.86% to $66.04 after the company reported Q2 results. The company reported earnings of $183 million, or $0.95 per share.
No comments:
Post a Comment